Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Bart Barlogie, MD, PhD, Elias J. Anaissie, MD, John D. Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Jeff Haessler, MD, Klaus A. Hollmig, MD, Yazan Alsayed, MD, Sarah Waheed, MD, Monica Graziutti, MD, Elias Kiwan, MD, John Crowley, PhD

Blood (2008) 112 (11): 162.

https://doi.org/10.1182/blood.V112.11.162.162

Published: 2008

Journal Articles

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Maurizio Zangari, MD, Federica Cavallo, MD, Louis M. Fink, MD, Bart Barlogie, MD, PhD, Vanessa Bolejack, BS, Michael J. Burns, Elias Anaissie, MD, Klaus A. Hollmig, MD, Abid Mohiuddin, MD, Mauricio Pineda-Roman, MD, Guido J. Tricot, MD, PhD

Blood (2006) 108 (11): 3573.

https://doi.org/10.1182/blood.V108.11.3573.3573

Published: 2006

Journal Articles

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Mauricio Pineda-Roman, MD, Michelle H. Fox, MD, Klaus A. Hollmig, MD, Elias J. Anaissie, MD, Frits van Rhee, MD,PhD, Guido Tricot, MD,PhD, Maurizio Zangari, MD, Abid Mohiuddin, MD, Bart Barlogie, MD,PhD

Blood (2006) 108 (11): 3102.

https://doi.org/10.1182/blood.V108.11.3102.3102

Published: 2006

Journal Articles

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

Maurizio Zangari, MD, Bart Barlogie, MD, PhD, Michael J. Burns, BS, BA, Vanessa Bolejack, MPH, Klaus A. Hollmig, MD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Francesca Elice, MD, Guido J. Tricot, MD, PhD

Blood (2005) 106 (11): 2552.

https://doi.org/10.1182/blood.V106.11.2552.2552

Published: 2005

Journal Articles

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Steve D. Strout, Laurie Jones-Jackson, MD, Ronald C. Walker, MD, Gary Purnell, MD, Jose A. Diaz, MD, Fariba Saghafifar, MD, Klaus A. Hollmig, MD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 1160.

https://doi.org/10.1182/blood.V104.11.1160.1160

Published: 2004

Journal Articles

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD, MS, Fariba Saghafifar, MD, Giampaolo Talamo, MD, Klaus A. Hollmig, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD.

Blood (2004) 104 (11): 935.

https://doi.org/10.1182/blood.V104.11.935.935

Published: 2004

Journal Articles

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Athanasios Fassas, MD, Li Dong, MD, Miceli H. Miceli, MD, Frits Van Rhee, MD, PhD, Klaus A. Hollmig, MD, Giampaolo Talamo, MD, Guido J. Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 5040.

https://doi.org/10.1182/blood.V104.11.5040.5040

Published: 2004

NARROW

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only